WO2003078462A3 - Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner - Google Patents
Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner Download PDFInfo
- Publication number
- WO2003078462A3 WO2003078462A3 PCT/US2003/007210 US0307210W WO03078462A3 WO 2003078462 A3 WO2003078462 A3 WO 2003078462A3 US 0307210 W US0307210 W US 0307210W WO 03078462 A3 WO03078462 A3 WO 03078462A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucose
- insulin
- dependent manner
- cells
- nucleotide sequence
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 4
- 108090001061 Insulin Proteins 0.000 title abstract 4
- 239000008103 glucose Substances 0.000 title abstract 4
- 229940125396 insulin Drugs 0.000 title abstract 4
- 230000001419 dependent effect Effects 0.000 title abstract 3
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 125000003729 nucleotide group Chemical group 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 230000003248 secreting effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 3
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 210000002660 insulin-secreting cell Anatomy 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003213803A AU2003213803A1 (en) | 2002-03-12 | 2003-03-11 | Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner |
EP03711495A EP1492815A2 (en) | 2002-03-12 | 2003-03-11 | Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner |
CA002479007A CA2479007A1 (en) | 2002-03-12 | 2003-03-11 | Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/097,230 US7141240B2 (en) | 2002-03-12 | 2002-03-12 | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
US10/097,230 | 2002-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003078462A2 WO2003078462A2 (en) | 2003-09-25 |
WO2003078462A3 true WO2003078462A3 (en) | 2004-03-18 |
Family
ID=28039142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/007210 WO2003078462A2 (en) | 2002-03-12 | 2003-03-11 | Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner |
Country Status (5)
Country | Link |
---|---|
US (1) | US7141240B2 (en) |
EP (1) | EP1492815A2 (en) |
AU (1) | AU2003213803A1 (en) |
CA (1) | CA2479007A1 (en) |
WO (1) | WO2003078462A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147881A2 (en) * | 2007-05-22 | 2008-12-04 | The Penn State Research Foundation | Methods and compositions relating to pbk1 |
NZ592821A (en) * | 2008-11-13 | 2012-06-29 | Baylor Res Inst | Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
RU2015129788A (en) | 2012-12-21 | 2017-01-30 | Санофи | EXENDIN-4 DERIVATIVES AS GLP1 / GIP DOUBLE AGONISTS OR GLP1 / GIP / GLUCAGON TRIPLE ANGONISTS |
TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
CN109563487A (en) * | 2016-07-18 | 2019-04-02 | 苏黎士联邦理工大学 | β cell is quasi- like cell |
CN107412741B (en) * | 2017-04-25 | 2021-04-20 | 莎穆(上海)生物科技有限公司 | Mineralized exenatide sustained-release system and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001039784A1 (en) * | 1999-12-06 | 2001-06-07 | The General Hospital Corporation | Pancreatic stem cells and their use in transplantation |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935000A (en) | 1986-04-03 | 1990-06-19 | East Carolina University | Extracellular matrix induction method to produce pancreatic islet tissue |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5344919A (en) | 1987-02-19 | 1994-09-06 | The Scripps Research Institute | Integrin from human epithelial cells |
US5895785A (en) | 1987-10-20 | 1999-04-20 | Ruth Korth | Treatment and prevention of disorders mediated by LA-paf or endothelial cells |
US5530023A (en) | 1987-10-20 | 1996-06-25 | Korth; Ruth | Production of binding sites for PAF, PAF analogues and PAF antagonists in endothelial cells |
US5219752A (en) | 1988-05-25 | 1993-06-15 | Teijin, Limited | Process for continuously culturing adherent animal cells |
US5654267A (en) | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5427940A (en) | 1991-06-03 | 1995-06-27 | Board Of Regents, The University Of Texas System | Engineered cells producing insulin in response to glucose |
US5744327A (en) | 1990-02-20 | 1998-04-28 | Board Of Regents, The University Of Texas System | Methods for producing insulin in response to non-glucose secretagogues |
US6004775A (en) | 1990-08-03 | 1999-12-21 | The Salk Institute For Biological Studies | DNA encoding IGFBP-4 |
US5792656A (en) | 1991-06-03 | 1998-08-11 | Board Of Regents, The University Of Texas System | Methods of preparing genetically engineered cells that produce insulin in response to glucose |
AU2228592A (en) | 1991-06-24 | 1993-01-25 | Pacific Biomedical Research, Inc. | Hormone-secreting cells maintained in long-term culture |
PT101031B (en) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY |
AU2882992A (en) | 1991-11-06 | 1993-06-07 | Arthur A. Axelrad | Cell culture medium |
DK36392D0 (en) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
US5846747A (en) | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
DK39892D0 (en) | 1992-03-25 | 1992-03-25 | Bernard Thorens | PEPTIDE |
US6071697A (en) | 1992-08-03 | 2000-06-06 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for testing the differentiation status in pancreatic cells of a mammal |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
FR2710654B1 (en) | 1993-09-30 | 1995-12-22 | Maryam Asfari | New insulin secreting cell lines, their methods of obtaining by genetic manipulation and their use in diabetic subjects in protected form. |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5534404A (en) | 1993-12-10 | 1996-07-09 | Cytotherapeutics, Inc. | Glucose responsive insulin secreting β-cell lines and method for producing same |
US5858973A (en) | 1994-02-23 | 1999-01-12 | The General Hospital Corporation | Transcription factor and uses therefor |
US6001647A (en) | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
US5587309A (en) | 1994-04-29 | 1996-12-24 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo |
FR2723315B1 (en) | 1994-08-02 | 1996-10-25 | Cird Galderma | METHOD AND COMPOSITION FOR STIMULATING DIFFERENTIATION OF PREADIPOCYTE CELLS AND RELATED THERAPEUTIC TREATMENTS |
US6156306A (en) * | 1994-08-17 | 2000-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pancreatic β-cells for allogeneic transplantation without immunosuppression |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5629194A (en) | 1994-10-21 | 1997-05-13 | Diacrin, Inc. | Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity |
US6110743A (en) | 1995-02-10 | 2000-08-29 | The Regents Of The University Of California | Development and use of human pancreatic cell lines |
US5723333A (en) | 1995-02-10 | 1998-03-03 | Regents Of The University Of California | Human pancreatic cell lines: developments and uses |
CA2213610C (en) | 1995-02-22 | 2013-12-03 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
EP0822834A4 (en) | 1995-04-07 | 2002-09-18 | Einstein Coll Med | Recombinant (beta)-cell and uses thereof |
US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
AU719614B2 (en) | 1995-11-30 | 2000-05-11 | Research Development Foundation | Screening assay for compounds stimulating somatostatin and insulin production |
US6110707A (en) * | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US5804421A (en) | 1996-10-30 | 1998-09-08 | Eastern Virginia Medical School Of The Medical College Fo Hampton Roads | High level of expression of ingap in bacterial and euraryotic cells |
US5861278A (en) | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
US5948623A (en) | 1996-12-31 | 1999-09-07 | Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. | Method for testing the differentiation status in pancreatic cells of a mammal |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
CA2283834A1 (en) | 1997-03-31 | 1998-10-08 | James Arthur Hoffmann | Glucagon-like peptide-1 analogs |
US5880261A (en) | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
US6132708A (en) | 1997-10-10 | 2000-10-17 | Oregon Health Sciences University | Liver regeneration using pancreas cells |
US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
CN1191273C (en) | 1999-05-17 | 2005-03-02 | 康久化学公司 | Long lasting insulinotropic peptides |
US6160022A (en) | 1999-07-19 | 2000-12-12 | University Of Florida | Chemical resection of pancreas |
CN102151337B (en) * | 2000-03-13 | 2014-03-12 | 恩根尼公司 | Compositions and methods for regulated protein expression in gut |
US6642003B2 (en) * | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
AU2002327430A1 (en) * | 2001-08-08 | 2003-02-24 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
-
2002
- 2002-03-12 US US10/097,230 patent/US7141240B2/en not_active Expired - Fee Related
-
2003
- 2003-03-11 AU AU2003213803A patent/AU2003213803A1/en not_active Abandoned
- 2003-03-11 EP EP03711495A patent/EP1492815A2/en not_active Withdrawn
- 2003-03-11 WO PCT/US2003/007210 patent/WO2003078462A2/en not_active Application Discontinuation
- 2003-03-11 CA CA002479007A patent/CA2479007A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001039784A1 (en) * | 1999-12-06 | 2001-06-07 | The General Hospital Corporation | Pancreatic stem cells and their use in transplantation |
Non-Patent Citations (7)
Title |
---|
CHEPURNY OLEG G ET AL: "Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: A strategy for production of pancreatic beta-cell lines for use in transplantation.", CELL & TISSUE RESEARCH, vol. 307, no. 2, February 2002 (2002-02-01), pages 191 - 201, XP002255080, ISSN: 0302-766X * |
DATABASE SWISSPROT [online] EBI; 1 November 1990 (1990-11-01), XP002255213, Database accession no. P01274 * |
HUI H ET AL: "Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells", DIABETES, NEW YORK, NY, US, vol. 50, no. 4, April 2001 (2001-04-01), pages 785 - 796, XP002226311, ISSN: 0012-1797 * |
HUI HONGXIANG ET AL: "Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.", ENDOCRINOLOGY, vol. 143, no. 9, September 2002 (2002-09-01), September, 2002, pages 3529 - 3539, XP002255079, ISSN: 0013-7227 * |
ORSKOV C ET AL: "COMPLETE SEQUENCES OF GLUCAGON-LIKE PEPTIDE-1 FROM HUMAN AND PIG SMALL INTESTINE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 264, no. 22, 5 August 1989 (1989-08-05), pages 12826 - 12829, XP000036795, ISSN: 0021-9258 * |
PERFETTI R ET AL: "Gene therapy of pancreatic-derived beta-cells with GLP-1 restores glucose-dependent insulin production.", DIABETOLOGIA, vol. 44, no. Supplement 1, August 2001 (2001-08-01), 37th Annual Meeting of the European Association for the Study of Diabetes;Glasgow, Scotland, UK; September 09-13, 2001, pages A 121, XP009017662, ISSN: 0012-186X * |
PERFETTI RICCARDO ET AL: "Transfection with GLP-1 to produce glucose-dependent insulin-secreting cells.", CELL TRANSPLANTATION, vol. 10, no. 6, 2001, 10th Anniversary Congress of the Cell Transplant Society;Keystone, Colorado, USA; October 14-17, 2001, pages 515 - 516, XP009017701, ISSN: 0963-6897 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003078462A2 (en) | 2003-09-25 |
CA2479007A1 (en) | 2003-09-25 |
US20030186436A1 (en) | 2003-10-02 |
EP1492815A2 (en) | 2005-01-05 |
US7141240B2 (en) | 2006-11-28 |
AU2003213803A1 (en) | 2003-09-29 |
AU2003213803A8 (en) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003078462A3 (en) | Cells transfected with a nucleotide sequence encoding glp-1 and secreting insulin in a glucose-dependent manner | |
Krawczyk et al. | Electrogenetic cellular insulin release for real-time glycemic control in type 1 diabetic mice | |
Deacon | Circulation and degradation of GIP and GLP-1 | |
VandenBerg et al. | Biologically inspired and chemically derived methods for glucose‐responsive insulin therapy | |
Drucker | Minireview: the glucagon-like peptides | |
WO2008150821A8 (en) | Modified nucleotide sequence encoding glucagon-like peptide-1 (glp-1) | |
Holst et al. | Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. | |
WO2006096829A3 (en) | Thyrotropin-releasing hormone analogs and method of use | |
CN108136136A (en) | The attachment device of low-power consumption | |
WO2006096565A3 (en) | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions | |
WO2007137802A3 (en) | Device and method for controlled delivery of chemical substances | |
WO2003072728A3 (en) | Cellular trans-differentiation | |
Hume et al. | Polymerizable superoxide dismutase mimetic protects cells encapsulated in poly (ethylene glycol) hydrogels from reactive oxygen species‐mediated damage | |
Holst | The physiology and pharmacology of incretins in type 2 diabetes mellitus | |
WO2002074045A3 (en) | Production of pancreatic islet cells and delivery of insulin | |
Burcelin et al. | Encapsulated, Genetically Engineered Cells, Secreting Glucagon‐like Peptide‐1 for the Treatment of Non‐insulin‐dependent Diabetes Mellitus | |
WO2003012084A3 (en) | Human glucose-dependent insulin-secreting cell line | |
Leja-Szpak et al. | Modulation of pancreatic enzyme secretion by melatonin and its precursor; L-tryptophan. Role of CCK and afferent nerves. | |
Rosen et al. | Effects of Sacral Neuromodulation on Urinary and Fecal Incontinence. | |
Ristic et al. | Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. | |
Kelly et al. | Function and expression of sulfonylurea, adrenergic, and glucagon‐like peptide 1 receptors in isolated porcine islets | |
Braun et al. | Chronic sacral bilateral neuromodulation. Using a minimal invasive implantation technique in patients with disorders of bladder function | |
WO2003077949A3 (en) | Methods of treating diabetes using pde 11a inhibitors | |
Drucker et al. | New developments in the biology of the glucagon‐like peptides GLP‐1 and GLP‐2 | |
WO2005084651A3 (en) | Methods for altering insulin secretion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2479007 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003711495 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003711495 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |